Answers are grounded in this paper and cite their sources.
Treating neonatal meningitis caused by drug-resistant bacteria is clinically challenging. Conventional explanations focus on antibiotic failure, but whether infection with a drug-resistant clinical isolate is associated with altered host responses to therapy remains unknown. To compare host blood–brain barrier (BBB) responses to ampicillin plus Meropenem therapy in neonatal meningitis caused by standard versus drug-resistant Escherichia coli strains and to determine whether differences underlie treatment difficulty. Using standard and clinically isolated ampicillin/Meropenem-resistant E. coli, we established hCMEC/D3 cell and neonatal mouse meningitis models. Combination therapy effects on BBB function, tight junctions, ABC transporters, and signaling pathways were compared via TEER measurement, immunoblotting, and immunohistochemistry. In infection with the standard strain, therapy was associated with inhibition of PKC-α/RhoA and activation of PI3K/AKT/mTOR, alongside downregulation of BCRP, restoration of BBB function, and reduced neuroinflammation. In contrast, in infection with the drug-resistant clinical isolate, the same therapy only partially mitigated damage. This infection was accompanied by host signaling dysregulation, characterized by persistent PKC-α/RhoA activity, uncoordinated PI3K/AKT/mTOR activation, and compensatory MRP1 upregulation despite BCRP downregulation. The treatment difficulty of meningitis caused by the drug-resistant clinical isolate was associated with disrupted host signaling coordination during therapy, which may impair BBB repair. Combining antibiotics with host signaling modulators may improve outcomes.
No takes yet. Share an insight, caveat, or question.
Lei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: